IMRX
NASDAQImmuneering Corporation
$6.11+0.21 (+3.56%)
News25/Ratings12
News · 26 weeks40-17%
2025-10-262026-04-19
Mix1990d
- Insider8(42%)
- Other7(37%)
- SEC Filings4(21%)
Latest news
25 items- PRImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients - NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated data from the Phase 2a clinical trial evaluating atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented a
- SECSEC Form DEFA14A filed by Immuneering CorporationDEFA14A - Immuneering Corp (0001790340) (Filer)
- SECSEC Form DEF 14A filed by Immuneering CorporationDEF 14A - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and BeyondAnalysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the genetic alterations most commonly associated with resistance to RAS inhibitors, providing molecular rationale to treat with atebimetinib early NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the presentation of new genetic data at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April
- PRImmuneering to Present at the 25th Annual Needham Virtual Healthcare ConferenceNEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About ImmuneeringImmuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company
- INSIDERCHIEF PEOPLE OFFICER Neufeld Leah R was granted 3,628 shares, increasing direct ownership by 14% to 29,598 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- PRImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and SurvivalNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Inhibitors of RAS, RAF, or MEK often provide only temporary benefit due to resistance, as tumors acquire new mutations or mechanisms of escape within the MAPK pathway. Atebimetinib, a novel Deep Cyclic
- SECSEC Form 10-K filed by Immuneering Corporation10-K - Immuneering Corp (0001790340) (Filer)
- SECImmuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 - - On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 - - Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 - - Ended 2025 with $217 million in cash, cash equivalents and marketable s
- PRImmuneering to Present at the Leerink Global Healthcare ConferenceNEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company's pipeline, platform, and business strategy. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET The presentation will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneerin
- PRImmuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceNEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company's pipeline, platform, and business strategy. Format: Company Presentation and 1x1 Investor Meetings Date/Time: Thursday, February 26, 2026, at 10:00 am ET The presentation will be webcast live and archived in the Inve
- INSIDERSEC Form 4 filed by CHIEF LEGAL OFFICER, SECRETARY Bookman Michael4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Brakewood Harold Eugene4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Hall Brett Matthew4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Matushansky Igor4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by SVP Finance, CAO Morales Mallory4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF PEOPLE OFFICER Neufeld Leah R4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT AND CEO Zeskind Benjamin J.4 - Immuneering Corp (0001790340) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immuneering CorporationSCHEDULE 13G/A - Immuneering Corp (0001790340) (Subject)
- INSIDERChief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERDirector Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immuneering CorporationSCHEDULE 13G/A - Immuneering Corp (0001790340) (Subject)
- INSIDERCHIEF PEOPLE OFFICER Neufeld Leah R bought $10,906 worth of shares (2,626 units at $4.15), increasing direct ownership by 11% to 25,970 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)